|
| dbGaP Submitter Subject ID (ID2) | Coriell Sample ID | Consent | Control | Gender | Race | Age | Baseline Max AMD Severity | Final Max AMD Severity |
| AR2_0198 | ED148952 | General Research Use | No | Female | White | 76 | 9 - AREDS AMD Severity Scale Step 7 | 11b - Neovascular AMD with end-stage disease (e.g., definite disciform scar, or photocoagulation scar), or two or more of the following five characteristics of neovascular AMD: SSR detachment, PED, subretinal/sub-RPE hemorrhage, hard exudate, or fibrous tissue |
| AR2_0587 | ED148716 | General Research Use | No | Female | White | 83 | 9 - AREDS AMD Severity Scale Step 6 | 9 - AREDS AMD Severity Scale Step 9 |
| AR2_2385 | ED149786 | General Research Use | No | Male | White | 85 | 9 - AREDS AMD Severity Scale Step 9 | 11b - Neovascular AMD with end-stage disease (e.g., definite disciform scar, or photocoagulation scar), or two or more of the following five characteristics of neovascular AMD: SSR detachment, PED, subretinal/sub-RPE hemorrhage, hard exudate, or fibrous tissue |
| AR2_2980 | ED149540 | General Research Use | No | Male | White | 76 | 9 - AREDS AMD Severity Scale Step 8 | 9 - AREDS AMD Severity Scale Step 9 |
| AR2_3067 | ED149289 | General Research Use | No | Male | White | 71 | 9 - AREDS AMD Severity Scale Step 8 | 11b - Neovascular AMD with end-stage disease (e.g., definite disciform scar, or photocoagulation scar), or two or more of the following five characteristics of neovascular AMD: SSR detachment, PED, subretinal/sub-RPE hemorrhage, hard exudate, or fibrous tissue |
| AR2_3347 | ED148556 | General Research Use | No | Male | White | 77 | 9 - AREDS AMD Severity Scale Step 9 | 10 - Central GA |
| AR2_3939 | ED149946 | General Research Use | No | Female | White | 71 | 9 - AREDS AMD Severity Scale Step 8 | 11b - Neovascular AMD with end-stage disease (e.g., definite disciform scar, or photocoagulation scar), or two or more of the following five characteristics of neovascular AMD: SSR detachment, PED, subretinal/sub-RPE hemorrhage, hard exudate, or fibrous tissue |
| AR2_0270 | ED148142 | General Research Use | No | Female | White | 59 | 9 - AREDS AMD Severity Scale Step 6 | 9 - AREDS AMD Severity Scale Step 9 |
| AR2_0854 | ED149866 | General Research Use | No | Male | White | 68 | 9 - AREDS AMD Severity Scale Step 7 | 9 - AREDS AMD Severity Scale Step 9 |
| AR2_2780 | ED149112 | General Research Use | No | Male | White | 73 | 9 - AREDS AMD Severity Scale Step 8 | 10 - Central GA |
| AR2_3434 | ED150004 | General Research Use | No | Female | White | 60 | 9 - AREDS AMD Severity Scale Step 9 | 9 - AREDS AMD Severity Scale Step 9 |
| AR2_2145 | ED149508 | General Research Use | No | Male | White | 81 | 9 - AREDS AMD Severity Scale Step 6 | 11b - Neovascular AMD with end-stage disease (e.g., definite disciform scar, or photocoagulation scar), or two or more of the following five characteristics of neovascular AMD: SSR detachment, PED, subretinal/sub-RPE hemorrhage, hard exudate, or fibrous tissue |
| AR2_3693 | ED148499 | General Research Use | No | Female | White | 71 | 9 - AREDS AMD Severity Scale Step 9 | 10 - Central GA |
| AR2_3986 | ED149088 | General Research Use | No | Female | White | 77 | 9 - AREDS AMD Severity Scale Step 9 | 11b - Neovascular AMD with end-stage disease (e.g., definite disciform scar, or photocoagulation scar), or two or more of the following five characteristics of neovascular AMD: SSR detachment, PED, subretinal/sub-RPE hemorrhage, hard exudate, or fibrous tissue |
| AR2_2199 | ED149414 | General Research Use | No | Female | White | 85 | 9 - AREDS AMD Severity Scale Step 9 | 11b - Neovascular AMD with end-stage disease (e.g., definite disciform scar, or photocoagulation scar), or two or more of the following five characteristics of neovascular AMD: SSR detachment, PED, subretinal/sub-RPE hemorrhage, hard exudate, or fibrous tissue |
| AR2_2902 | ED149208 | General Research Use | No | Male | White | 74 | 9 - AREDS AMD Severity Scale Step 8 | 11b - Neovascular AMD with end-stage disease (e.g., definite disciform scar, or photocoagulation scar), or two or more of the following five characteristics of neovascular AMD: SSR detachment, PED, subretinal/sub-RPE hemorrhage, hard exudate, or fibrous tissue |
| AR2_3651 | ED148225 | General Research Use | No | Male | White | 72 | 9 - AREDS AMD Severity Scale Step 9 | 10 - Central GA |
| AR2_3694 | ED149922 | General Research Use | No | Male | White | 71 | 9 - AREDS AMD Severity Scale Step 7 | 11b - Neovascular AMD with end-stage disease (e.g., definite disciform scar, or photocoagulation scar), or two or more of the following five characteristics of neovascular AMD: SSR detachment, PED, subretinal/sub-RPE hemorrhage, hard exudate, or fibrous tissue |
| AR2_3726 | ED149876 | General Research Use | No | Male | White | 84 | 9 - AREDS AMD Severity Scale Step 7 | 11b - Neovascular AMD with end-stage disease (e.g., definite disciform scar, or photocoagulation scar), or two or more of the following five characteristics of neovascular AMD: SSR detachment, PED, subretinal/sub-RPE hemorrhage, hard exudate, or fibrous tissue |
| AR2_4031 | ED148996 | General Research Use | No | Female | White | 78 | 9 - AREDS AMD Severity Scale Step 9 | 11b - Neovascular AMD with end-stage disease (e.g., definite disciform scar, or photocoagulation scar), or two or more of the following five characteristics of neovascular AMD: SSR detachment, PED, subretinal/sub-RPE hemorrhage, hard exudate, or fibrous tissue |